Marker Therapeutics, Inc. (MRKR) financial statements (2022 and earlier)

Company profile

Business Address 3200 SOUTHWEST FREEWAY
HOUSTON, TX 77027
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42,35121,35243,90461,7475,1297,8516,577
Cash and cash equivalents42,35121,35243,90461,7475,1297,8516,577
Restricted cash and investments1,146      
Receivables01,000 108   
Prepaid expense2,4852,0581,5261425170 
Other undisclosed current assets 156   69
Total current assets:45,98224,41145,48761,9975,1807,9216,645
Noncurrent Assets
Operating lease, right-of-use asset9,83010,844455
Property, plant and equipment  418148   
Prepaid expense      69
Other undisclosed noncurrent assets12,32210,360     
Total noncurrent assets:22,15321,204873148  69
TOTAL ASSETS:68,13545,61546,35962,1445,1807,9216,714
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:11,1356,0131,7582,7551,5081,225 
Accounts payable5,1442,9359931,6191,015680 
Accrued liabilities8941,279337342116128 
Employee-related liabilities2,0551,694323416162218 
Other undisclosed accounts payable and accrued liabilities3,042105105378215200 
Deferred revenue1,146  
Debt  204 5530
Derivative instruments and hedges, liabilities  314991526,493
Other liabilities     492492
Other undisclosed current liabilities620389    990
Total current liabilities:12,9026,4021,9932,8041,5221,73728,006
Noncurrent Liabilities
Long-term debt and lease obligation11,24811,868280    
Operating lease, liability11,24811,868280
Other undisclosed noncurrent liabilities(11,248)(11,868)     
Total noncurrent liabilities:11,24811,868280    
Total liabilities:24,15018,2702,2732,8041,5221,73728,006
Stockholders' equity
Stockholders' equity attributable to parent43,98627,34544,08659,3413,6586,185(21,360)
Common stock8351464511871
Additional paid in capital442,021383,533371,574365,401161,068151,992112,078
Accumulated deficit(398,118)(356,239)(327,533)(306,105)(157,420)(145,816)(133,508)
Total stockholders' equity:43,98627,34544,08659,3413,6586,185(21,360)
TOTAL LIABILITIES AND EQUITY:68,13545,61546,35962,1445,1807,9216,645

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1,2424672132062002 
Revenue, net200  
Other income     2 
Gross profit:1,2424672132062002 
Operating expenses(40,720)(29,353)(22,742)(148,378)(11,663)(8,492)(6,159)
Other undisclosed operating loss    (200)(2) 
Operating loss:(39,478)(28,886)(22,529)(148,172)(11,663)(8,492)(6,159)
Nonoperating income (expense)61491,083254  (9,312)
Investment income, nonoperating61491,083254  (9,313)
Interest and debt expense    492(136)(11)
Loss before gain (loss) on sale of properties:(39,472)(28,737)(21,446)(147,918)(11,171)(8,628)(15,482)
Other undisclosed net income (loss)(2,407)3118   (18,584)
Net loss:(41,879)(28,706)(21,428)(147,918)(11,171)(8,628)(34,066)
Other undisclosed net income (loss) attributable to parent   (40)1896,173 
Net loss available to common stockholders, basic:(41,879)(28,706)(21,428)(147,958)(10,982)(2,455)(34,066)
Dilutive securities, effect on basic earnings per share     (2,856) 
Net loss available to common stockholders, diluted:(41,879)(28,706)(21,428)(147,958)(10,982)(5,311)(34,066)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(41,879)(28,706)(21,428)(147,918)(11,171)(8,628)(34,066)
Other comprehensive loss      (34,066)
Comprehensive loss, net of tax, attributable to parent:(41,879)(28,706)(21,428)(147,918)(11,171)(8,628)(68,133)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: